Certara Announces Proposed Public Offering of Common Stock
15 nov. 2021 17h30 HE
|
Certara
PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering by certain selling...
Certara Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h10 HE
|
Certara
PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2021. ...
Certara Appoints James E. Cashman III as Chairman of Board of Directors
08 nov. 2021 16h30 HE
|
Certara
PRINCETON, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that James E. Cashman III, a current Board member, will be...
Certara to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
03 nov. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William F. Feehery, Chief Executive Officer, and Andrew...
Pinnacle 21 Awarded FDA Contract for 5 Years for Software and Services
28 oct. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has awarded a...
Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award
25 oct. 2021 16h30 HE
|
Certara
PRINCETON, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that its Simcyp COVID-19 Vaccine Model has won an R&D 100...
Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021
19 oct. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of...
Certara 推出全新 Synchrogenix™ Writer 软件，加速监管审批流程
12 oct. 2021 23h40 HE
|
Certara USA, Inc.
新泽西州普林斯顿, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Certara 为全球生物模拟领域的领军企业，今日宣布推出一款全新的监管 SaaS 产品——Synchrogenix™ Writer。该产品可加快患者叙述的撰写和审查速度。患者叙述描述了不良事件或药物不良反应，对于整个临床阶段的每个治疗领域的临床研究报告都至关重要。 ...
Certara Appoints Patrick F. Smith to President of Integrated Drug Development
12 oct. 2021 08h00 HE
|
Certara
PRINCETON, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Patrick F. Smith, Pharm.D. as president of...
Certara 完成对Pinnacle 21 的收购
11 oct. 2021 22h12 HE
|
Certara USA, Inc.
新泽西州普林斯顿, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Certara, Inc.（纳斯达克代码：CERT）为全球生物模拟领域的领军企业，今日宣布完成此前公布的 Pinnacle 21 收购交易，Pinnacle 21 为面向临床数据拟合、监管合规和审批准备的 SaaS 解决方案领先提供商。该交易完成后，Pinnacle 21 的股权持有人获得了约 2.5...